Loading clinical trials...

RECRUITINGPHASE4

The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial

NCT07127354•The Cleveland Clinic

Summary

The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adult patient (Age 18 years or older)
•Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
•Using a GLP-1 or GIP agonist at a stable dose for at least one month

Exclusion Criteria

•Unable to provide informed consent, e.g., dementia
•Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
•Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:
•1. Cirrhosis
•2. Parkinson's disease
•3. Dementia
•4. Tricyclic antidepressant use
•5. Opioid use
•6. Gastroparesis\* or suspected gastric outlet obstruction on pre-procedure imaging (\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)
•7. Previous colorectal surgery
+1 more criteria

Locations (3)

Cleveland Clinic

Cleveland, Florida, United States

Cleveland Clinic

Cleveland, Florida, United States

Cleveland Clinic Weston

Weston, Florida, United States

Key Dates

Start Date

August 1, 2025

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

December 4, 2025

Enrollment

132

ESTIMATED participants

Conditions

GLP - 1Bowel Preparation for Colonoscopy

Interventions

Continue GLP/GIP

DRUG

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324

Obesity PreventionSarcopenia in Elderly+3 more

View study

UNKNOWNPHASE4

Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy

NCT02781493

Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

Inclusion Criteria

Exclusion Criteria

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy

Low-volume Polyethylene Glycol Bowel Preparation for Colonoscopy

Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients